Resistance in Hepatitis C
Source: Clinical Implications of HCV Resistance: Laying the Foundation for Optimal Treatment Today and in the Future

Module

Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply strategies to reduce the development/expansion of resistance to direct-acting antiviral agents when managing patients receiving treatment with approved direct-acting antiviral agents in combination with peginterferon/ribavirin
  • Integrate key principles regarding antiviral resistance when evaluating data on the direct-acting antiviral agents currently in development
  • Evaluate potential future strategies for HCV treatment based on resistance considerations, including the barrier to resistance and patterns of cross-resistance among classes of direct-acting antiviral agents

Topics covered include:

  • Introduction to Drug Resistance in Hepatitis C Virus
  • Key Resistance Principles for Currently Approved Direct-Acting Antiviral Agents
  • Considerations for Retreatment of Previous Peginterferon/Ribavirin Null Responders and Potential Consequences of Protease Inhibitor Resistance
  • Genotype and Resistance Testing
  • Case 1: Previous Null Responder
  • Case 2: Stopping Rules
  • Case 3: Boceprevir Resistance–Associated Variant
  • Future Regimens
  • Future Protease Inhibitors
  • Nucleos(t)ide Polymerase Inhibitors
  • Nonnucleos(t)ide Polymerase Inhibitors
  • NS5A Inhibitors
  • Cyclophilin Inhibitors
  • Summary: Important Considerations to Avoid Resistance-Associated Variants
  • Appendix: Principles of HCV Resistance
 

Program Directors

  • Stefan Zeuzem
    MD

Faculty

  • Stéphane Chevaliez
    PharmD, PhD
    Paul J. Pockros
    MD

Credit Information

  • Release Date:
    October 25, 2011
  • Expiration Date:
    October 24, 2012
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits
  • Drug Users and HCV Providers: How Do We Work Together to Achieve HCV Treatment Success?

    Gregory Dore  - 9/24/2013    2 comments / Last Comment: 11/9/2013
    Injecting drugs is a path to hepatitis C infection, but that path is not a dead end when providers join the journey to a cure with careful patient selection and understanding.
  • Post-CROI Update: How I Manage HIV/HCV-Coinfected Patients

    Jürgen K. Rockstroh MD - 4/9/2014    
    How should HIV treaters apply the latest HCV study results and guidelines to the management of coinfected patients?
  • Coffee May Offer Real Benefits to the Liver

    Mark S. Sulkowski MD - 8/13/2013    7 comments / Last Comment: 11/30/2013
    The latest prescription for liver health in patients with hepatitis: coffee.
  • Enter the Nonspecialist: Will Evolving Hepatitis C Therapies Reduce the Need for Specialized Care?

    Graham R. Foster FRCP, PhD - 10/8/2013    20 comments / Last Comment: 2/5/2014
    As therapeutic options for hepatitis C therapy evolve with reduced dosing requirements and improved adverse event profiles, the need for specialist care will diminish.
  • Don’t Marginalize Your HCV-Infected PWID—Treat Them

    Jason Grebely BSc, PhD - 9/16/2013    1 comment / Last Comment: 10/8/2013
    Even people who use drugs can achieve successful outcomes with hepatitis C therapy, with low reinfection rates.